Suppr超能文献

[黑色素瘤:影像学介绍及特殊要求]

[Melanoma: introduction and special demands on radiology].

作者信息

Schiller M, Hassel J C

机构信息

Universitätshautklinik, Nationales Centrum für Tumorerkrankungen, Im Neuenheimer Feld 460, 69120, Heidelberg, Deutschland.

出版信息

Radiologe. 2015 Feb;55(2):93-8. doi: 10.1007/s00117-014-2758-8.

Abstract

CLINICAL ISSUE

The incidence of melanoma has rapidly increased in the last decades. Most relevant for patient prognosis is the tumor thickness, hence an early diagnosis is crucial.

STANDARD TREATMENT

The basis of treatment is at the primary tumor stage and excision of regional metastases with curative intention.

TREATMENT INNOVATIONS

Targeted therapies, such as BRAF and MEK inhibitors have the advantage of a rapid response even in highly advanced stages of the disease.

DIAGNOSTIC WORK-UP: For routine diagnostics ultrasound, computed tomography (CT), fluorodeoxyglucose positron emission tomography CT (FDG-PET/CT) and magnetic resonance imaging (MRI) are used.

PERFORMANCE AND ACHIEVEMENTS

In the treatment of distant metastases new treatment options are available which more than doubled patient survival rates. Especially immune therapies with immune checkpoint blockers, such as ipilimumab or PD-1 antibodies can lead to long-term survival of patients. In contrast to chemotherapy these new substances have characteristics which make new demands on radiologists related to the possibility of pseudoprogression in immune therapies, which make it necessary to use other response criteria. In addition, autoimmune phenomena, such as a sarcoid-like reactions may mimic new metastases and should be included in the differential diagnosis. BRAF inhibitors may lead to cystic conversions of metastases which again require an evaluation beyond the response evaluation criteria in solid tumors (RECIST), e.g. with the adapted Choi criteria.

PRACTICAL RECOMMENDATIONS

Close interdisciplinary communication, functional imaging methods and adapted response criteria, such as the immune-related response criteria will optimize radiological evaluations of melanoma.

摘要

临床问题

在过去几十年中,黑色素瘤的发病率迅速上升。对患者预后最相关的是肿瘤厚度,因此早期诊断至关重要。

标准治疗

治疗的基础是在原发性肿瘤阶段,以治愈为目的切除区域转移灶。

治疗创新

靶向治疗,如BRAF和MEK抑制剂,即使在疾病的高度进展阶段也具有快速反应的优势。

诊断检查

常规诊断使用超声、计算机断层扫描(CT)、氟脱氧葡萄糖正电子发射断层扫描CT(FDG-PET/CT)和磁共振成像(MRI)。

性能与成就

在远处转移的治疗中,有新的治疗选择,患者生存率提高了一倍多。特别是使用免疫检查点阻断剂的免疫疗法,如伊匹单抗或PD-1抗体,可使患者长期存活。与化疗不同,这些新物质具有一些特性,对放射科医生提出了新的要求,因为免疫疗法中可能出现假性进展,这就需要使用其他反应标准。此外,自身免疫现象,如结节样反应,可能会模仿新的转移灶,应纳入鉴别诊断。BRAF抑制剂可能导致转移灶的囊性转化,这同样需要超出实体瘤反应评估标准(RECIST)的评估,例如采用改良的Choi标准。

实用建议

密切的多学科沟通、功能成像方法和适应性反应标准,如免疫相关反应标准,将优化黑色素瘤的放射学评估。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验